Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database

Psychiatry Clin Neurosci. 2022 Sep;76(9):475-477. doi: 10.1111/pcn.13432. Epub 2022 Jul 2.

Authors

Masahiro Takeshima¹, Minori Enomoto², Masaya Ogasawara¹, Mizuki Kudo¹, Yu Itoh¹, Kazuhisa Yoshizawa¹, Dai Fujiwara¹, Yoshikazu Takaesu³, Kazuo Mishima¹

Affiliations

¹ Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
² Department of Medical Technology, School of Health Sciences, Tokyo University of Technology, Tokyo, Japan.
³ Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

No abstract available

Publication types

Letter

MeSH terms

Humans
Japan
Policy
Polypharmacy*
Prescriptions
Psychotropic Drugs* / therapeutic use

Substances

Psychotropic Drugs

Grants and funding

R3-21GC1016/Japanese Ministry of Health, Labour and Welfare